Short-term DAPT for Coronary Artery Disease
(ODIN Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop your current medications, but you cannot participate if you are using oral anticoagulants or certain strong medications like ketoconazole or clarithromycin. It's best to discuss your current medications with the trial team.
What data supports the effectiveness of the drug Ticagrelor for coronary artery disease?
Ticagrelor is an antiplatelet drug used to reduce the risk of heart-related events in patients with acute coronary syndrome, and it has been shown to be effective when used with aspirin. It works by preventing blood cells called platelets from clumping together, which helps prevent blood clots.12345
How does the drug Ticagrelor differ from other treatments for coronary artery disease?
Ticagrelor is unique because it is a direct inhibitor of the ADP P2Y12 receptor, which means it doesn't need to be activated by the body to work, unlike some other drugs. It also has a rapid onset and offset of action, making it effective quickly and allowing for flexible treatment durations, such as short-term dual antiplatelet therapy (DAPT) followed by monotherapy, which can reduce bleeding risks compared to standard DAPT.35678
What is the purpose of this trial?
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
Research Team
Marc Ruel, MD, MPH
Principal Investigator
Ottawa Heart Institute Research Corporation
Mario Gaudino, MD, PhD, MSCE
Principal Investigator
Weill Medical College of Cornell University
Eligibility Criteria
This trial is for adults over 18 who need their first coronary artery bypass graft using a saphenous vein and can follow the study for at least 5 years. It's not for women who could get pregnant, people with recent heart issues or surgeries, those on blood thinners or with certain health conditions like severe liver failure, cancer, or expected short lifespan.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive ticagrelor plus low-dose aspirin or low-dose aspirin alone for one month
Follow-up
Participants are monitored for safety and effectiveness after treatment, including imaging follow-up at 12 months
Long-term follow-up
Participants are monitored for long-term outcomes, including quality of life assessments over 5 years
Treatment Details
Interventions
- Ticagrelor
- Ticagrelor placebo
Ticagrelor is already approved in United States, European Union for the following indications:
- Acute coronary syndrome (ACS)
- Cardiovascular event prevention
- Coronary artery disease (CAD)
- Acute ischemic stroke
- Transient ischemic attack (TIA)
- Acute coronary syndrome (ACS)
- Cardiovascular event prevention
- Coronary artery disease (CAD)
- Acute ischemic stroke
- Transient ischemic attack (TIA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Weill Medical College of Cornell University
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator